ECCO Cardiovascular Disorders Practice Test

Patients with drug-eluting coronary stents are typically prescribed a P2Y12 inhibitor for a duration of one year. The rationale behind this extended therapy is to prevent stent thrombosis, which is a critical complication that can lead to serious cardiovascular events. The use of a P2Y12 inhibitor, such as clopidogrel or ticagrelor, effectively inhibits platelet activation and aggregation, thereby reducing the risk of clot formation around the stent.

The duration of one year is supported by clinical trials and guidelines that demonstrate the benefits of long-term antiplatelet therapy in maintaining stent patency and improving patient outcomes. While shorter durations of therapy may be appropriate in certain high-risk populations or in cases of higher bleeding risk, the one-year recommendation is considered standard for most patients receiving drug-eluting stents. This ensures a balance between preventing thrombotic events and minimizing the risk of bleeding complications.